Medication for Hot Flashes: SSRIs, SNRIs, Gabapentin, and More
Dr. Karla Loken is a board-certified OB/GYN with over two decades of clinical experience and a distinguished career driving innovation in women's health across the pharmaceutical, diagnostics, and medical device industries. Through her consultancy, Loken & Associates, Dr. Loken provides medical affairs expertise and fractional Chief Medical Officer (CMO) services, helping early-stage companies bridge the gap between scientific innovation and industry application. She serves as Chief Medical Officer to MenoHealth. · 15 min read · Sep 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on September 20, 2026
Medication for hot flashes: SSRIs, SNRIs, gabapentin, oxybutynin, clonidine, and fezolinetant. What works, what each does, and when each is preferred.
Hormone therapy for menopause is rife with confusion, fear, misunderstanding, and outright misinformation. Even doctors — who are often relying on long-debunked research — can be at a loss to help women make educated choices for their health and well-being.
If you’re searching for medication for hot flashes, you’ve probably already decided that white-knuckling it isn’t working — and you’re trying to figure out which prescription option actually fits your situation. The honest answer is that several non-hormonal medications work, the evidence for each is uneven, and which one is preferred depends on what else is going on in your health and your day.
This guide walks through the non-hormonal prescription options with the strongest clinical evidence — SSRIs and SNRIs, gabapentin, oxybutynin, clonidine, and the newer neurokinin-receptor antagonist fezolinetant — what the trials actually showed, and how specialists decide which to recommend first.
Key takeaways
Several non-hormonal medications meaningfully reduce hot flash frequency and severity. None work as well as systemic hormone therapy, but for women who can’t or don’t want hormones, they’re a credible second line.
The strongest non-hormonal evidence is for low-dose paroxetine (the only SSRI with FDA approval specifically for vasomotor symptoms), escitalopram, venlafaxine, and gabapentin, based on the MsFLASH trials and confirmed in The Menopause Society’s 2023 Nonhormone Therapy Position Statement.
Each option has a different side-effect profile and is preferred in different clinical contexts — for example, an SNRI when mood symptoms are also present, gabapentin when night sweats and sleep are the dominant complaint.
Fezolinetant (Veozah) is a newer FDA-approved non-hormonal option specifically for moderate-to-severe vasomotor symptoms, with a different mechanism than the older medications.
Medication for hot flashes always requires evaluation by a clinician who knows your full history. There is no over-the-counter version of any of these.
The short answer: which medication for hot flashes works
The non-hormonal medications with the strongest randomized-trial evidence for hot flashes are low-dose paroxetine, escitalopram, venlafaxine, gabapentin, oxybutynin, and fezolinetant. All are endorsed in the Menopause Society’s 2023 Nonhormone Therapy Position Statement as having sufficient evidence to recommend for women with moderate-to-severe vasomotor symptoms (VMS) who don’t use hormone therapy.
Each typically reduces hot flash frequency by roughly 30 to 60 percent over placebo in trials, which is meaningful — but consistently less than the 70 to 90 percent reduction seen with systemic estrogen. They are a serious second line, not a perfect substitute.
Why non-hormonal medication for hot flashes exists
Hormone therapy is the most effective treatment for vasomotor symptoms and remains the position of every major menopause society. But it isn’t appropriate for everyone — it’s contraindicated in women with a history of estrogen-sensitive breast cancer, certain cardiovascular events, or active liver disease — and many women who could safely use it choose not to.
For those women, a handful of medications originally developed for other indications meaningfully reduce hot flash frequency and severity. The mechanism, for most of them, runs through the brain’s thermoregulatory centers rather than the ovaries.
If you’re still weighing hormonal vs. non-hormonal approaches, our overview of how to stop hot flashes walks through the full landscape before you narrow in on medication.
SSRIs and SNRIs: the antidepressant class that helps hot flashes
HRT is a treatment that is safe, very similar to your body's hormones, and doctor-recommended. There shouldn't be so much stigma around hormone therapy because the benefits outweigh the risks.
The largest body of randomized-trial evidence for non-hormonal medication for hot flashes comes from the MsFLASH trials (Menopause Strategies: Finding Lasting Answers for Symptoms and Health), an NIH-funded network conducted at multiple US sites in the 2010s.
Joffe and colleagues, publishing in JAMA Internal Medicine in 2014, reported that low-dose venlafaxine (75 mg/day) reduced hot flash frequency by approximately 48 percent compared to about 29 percent for placebo over eight weeks. An earlier MsFLASH trial of low-dose escitalopram (10–20 mg/day) showed a similar magnitude of benefit, and a 2003 trial of low-dose paroxetine led by Stearns and colleagues was the original signal that this drug class worked at all.
Paroxetine
Low-dose paroxetine (7.5 mg/day, marketed as Brisdelle in the US) is the only medication in this class with FDA approval specifically for moderate-to-severe vasomotor symptoms of menopause. The dose is well below what’s used to treat depression, which matters for tolerability.
Paroxetine is generally well-tolerated at this dose, but there’s an important interaction to flag: paroxetine inhibits CYP2D6, the enzyme that converts tamoxifen into its active metabolite. Women on tamoxifen for breast cancer should not use paroxetine for hot flashes — venlafaxine or gabapentin are preferred instead. Our guide on tamoxifen side effects covers this interaction in detail.
Escitalopram
Low-dose escitalopram (10–20 mg/day) has the strongest MsFLASH evidence of any SSRI for vasomotor symptoms. It’s a reasonable first choice when mood symptoms — anxiety, low mood, irritability — are coexisting with hot flashes, because the dose used for VMS is in the same range used for anxiety and depression. The same medication, in other words, can address both problems.
Venlafaxine
Venlafaxine, an SNRI, is the most commonly used non-hormonal medication for VMS in oncology settings. The MsFLASH head-to-head data put it roughly on par with low-dose estradiol patch for VMS reduction — a striking finding that underpins much of its use in breast cancer survivors. Low-dose venlafaxine (37.5–75 mg/day) is generally well-tolerated, and because it doesn’t significantly inhibit CYP2D6 at these doses, it’s the preferred SNRI for women on tamoxifen.
Desvenlafaxine
There's a lot of chatter around hormone replacement therapy. A lot of fear mongering, a lot of 'only I can do this for you the right way.' What I tell all my patients is that HRT is the replacing of the endocrine factors — the estrogen and progesterone — that have gone missing from a woman's body.
Desvenlafaxine, the active metabolite of venlafaxine, has positive trial data for VMS as well, though it’s not FDA-approved for this indication. It’s a reasonable option in women who have had trouble with venlafaxine specifically.
What to expect
Across this class, benefits typically appear within two to four weeks. Side effects — nausea, dry mouth, reduced libido, sleep changes — also tend to appear early and often improve within the first month. Stopping these medications abruptly can cause discontinuation symptoms, so taper rather than stopping cold.
If symptoms haven’t meaningfully improved after eight weeks at a therapeutic dose, the medication isn’t going to work for you. That’s useful information — switching to a different mechanism (gabapentin, oxybutynin, fezolinetant) is reasonable.
Gabapentin
Gabapentin, originally developed as an anti-seizure medication, has a separate evidence base supporting use for VMS, particularly night sweats. The magnitude of hot flash reduction in trials is similar to that seen with SSRIs and SNRIs — roughly a 45 to 50 percent reduction in frequency versus placebo.
What makes gabapentin distinctive is that it tends to help sleep. The most common dosing strategy concentrates the dose at bedtime, which is also when its sedating effect helps women who are being woken by night sweats. For someone whose dominant complaint is “I’m not sleeping because I’m soaked every two hours,” gabapentin is often the preferred non-hormonal option.
The trade-off is that the same sedation can be a problem in the morning. Daytime drowsiness, dizziness, and unsteadiness are the most common reasons women stop gabapentin. Starting low and titrating up over a week or two helps. Gabapentin is renally cleared, so dosing has to be adjusted in women with reduced kidney function.
For more on the sleep dimension specifically, our explainers on menopause night sweats and menopause insomnia walk through how sleep and VMS interact and what treatments target each.
Oxybutynin
Oxybutynin is an anticholinergic medication originally used for overactive bladder. It has a smaller but consistent body of trial evidence for VMS — reductions in hot flash frequency in the same general range as SSRIs and gabapentin.
The Menopause Society’s 2023 statement includes oxybutynin among the recommended non-hormonal options. Its main limitation is the anticholinergic side-effect profile: dry mouth, constipation, blurred vision, and cognitive effects, particularly in older women. Long-term anticholinergic use has been associated in observational studies with increased risk of cognitive impairment, which is why most specialists avoid oxybutynin as a first choice in women over 65 or when other options are reasonable.
For a younger woman with severe VMS who has already tried and not tolerated an SSRI/SNRI and gabapentin, oxybutynin is a credible next step — particularly if she also has bladder urgency symptoms that the same medication can address.
Clonidine
Clonidine is an older antihypertensive that was one of the first non-hormonal medications studied for hot flashes. The trial evidence for clonidine is weaker than for SSRIs/SNRIs or gabapentin, and side effects — dry mouth, low blood pressure, sedation — are common at doses that produce meaningful VMS benefit.
Clonidine remains a recommended option in NICE Guideline NG23 (updated November 2024) for women who can’t take other non-hormonal medications, but in current US menopause practice it’s used less often than the newer options. It’s worth knowing about, particularly if you have hypertension that could be co-managed with the same medication.
Fezolinetant (Veozah)
Fezolinetant is a neurokinin-3 receptor antagonist — a new class of medication that targets the KNDy neurons in the hypothalamus thought to drive the brain’s misfired thermoregulatory response that produces hot flashes. It was FDA-approved in 2023 for moderate-to-severe vasomotor symptoms specifically.
The Phase 3 trials — SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 — showed reductions in both frequency and severity of hot flashes that were larger than what’s typically seen with SSRIs or gabapentin, though still less than systemic estrogen. Fezolinetant is generally well-tolerated. The main safety signal is hepatic: liver enzyme elevations were reported in trials, and the FDA label requires baseline and periodic liver function testing during treatment.
Fezolinetant is meaningful because it offers a credible non-hormonal option with a different mechanism — useful for women who have not tolerated SSRIs or gabapentin, or who have a clinical reason to avoid those classes. It is also expensive and not always covered without prior authorization. Our full breakdown on Veozah (fezolinetant) covers the trial data, the liver-testing requirement, and who’s a candidate.
How clinicians decide which medication for hot flashes to recommend first
The choice depends on the rest of your clinical picture. Common patterns:
Coexisting depression or anxiety: an SSRI (escitalopram) or SNRI (venlafaxine) is often preferred, because a single medication can address both.
Sleep disruption from night sweats is the dominant symptom: gabapentin at bedtime, because its sedating effect is useful rather than a problem.
History of breast cancer and tamoxifen use: paroxetine is avoided (CYP2D6 interaction). Venlafaxine, gabapentin, or fezolinetant are typical first choices — covered in the tamoxifen side effects guide.
Coexisting overactive bladder: oxybutynin can address both, though its tolerability ceiling limits use in older women.
Tried SSRI/SNRI and gabapentin without benefit: fezolinetant is a reasonable next step, given baseline liver testing is acceptable.
These are starting points, not algorithms.
What non-hormonal medication for hot flashes does not do
None of the non-hormonal medications matches systemic estrogen for VMS reduction. The honest framing from the Menopause Society’s 2023 Nonhormone Position Statement is that they’re a meaningful but partial answer — typically reducing hot flash frequency by about half rather than nearly eliminating them.
They also don’t address other menopause symptoms hormone therapy treats: vaginal dryness and painful sex (those need local vaginal estrogen or an alternative), or bone-loss prevention. If those are part of your picture, raise them with your clinician — the Menopause Society 2022 Hormone Therapy Position Statement outlines when hormone therapy is appropriate even for women who initially assumed it wasn’t.
What this means for you
Three things are worth knowing going into a clinician visit:
The class matters more than the specific drug, early on. The first decision is usually which mechanism fits your situation.
Give each drug a fair trial. Eight weeks at a therapeutic dose is the rough benchmark. Early side effects often fade.
Track what you’re taking and what changes. Counting hot flashes before and after starting a medication, including night-time episodes, is the cleanest signal — memory is unreliable.
When to talk to your doctor
Every medication in this article requires prescription and clinical evaluation. Reasonable triggers to start that conversation:
Hot flashes or night sweats severe enough to disrupt sleep, work, or daily function
A medical history that rules out hormone therapy (breast cancer, certain cardiovascular events, active liver disease)
A personal preference not to use hormone therapy after an informed discussion
Coexisting depression, anxiety, or insomnia that a single medication might address alongside VMS
Previous trials of lifestyle and behavioral approaches that haven’t been enough
Concerns about a medication you’ve already been prescribed — whether the dose is right, whether the side effects you’re having are expected, whether to switch
A clinician who specializes in menopause will know the current evidence and the practical differences between options. If you’d like a structured way to prepare, our guide on talking to your doctor about menopause walks through what to bring and what to ask.
Frequently asked questions
What is the best non-hormonal medication for hot flashes?
There’s no single best option. The strongest evidence is for low-dose paroxetine (the only FDA-approved option in its class for VMS), escitalopram, venlafaxine, gabapentin, oxybutynin, and fezolinetant. The right first choice depends on your other health conditions, current medications, and which symptoms are most disruptive.
Do SSRIs work for hot flashes if I’m not depressed?
Yes. The doses of SSRIs used to treat vasomotor symptoms are typically lower than antidepressant doses, and the mechanism — modulation of thermoregulatory pathways in the brain — is thought to be independent of the antidepressant effect. The MsFLASH trials confirmed efficacy in women without depression.
Can I take paroxetine for hot flashes if I’m on tamoxifen?
Generally no. Paroxetine inhibits the CYP2D6 enzyme that converts tamoxifen into its active form, which may reduce tamoxifen’s effectiveness. Venlafaxine, gabapentin, or fezolinetant are preferred non-hormonal options for women on tamoxifen.
How long does it take for medication for hot flashes to work?
For SSRIs/SNRIs and gabapentin, most women notice benefit within two to four weeks, with maximal effect by about eight weeks. Fezolinetant trials showed meaningful reductions within four weeks. If a medication hasn’t helped at a therapeutic dose after eight weeks, it’s reasonable to switch.
Is fezolinetant safer than SSRIs or gabapentin for hot flashes?
“Safer” depends on what risks matter to you. Fezolinetant has a specific requirement for liver function monitoring that the older medications don’t. SSRIs/SNRIs have a sexual side-effect profile fezolinetant doesn’t. Gabapentin can cause daytime sedation fezolinetant doesn’t. Each profile fits different women.
Can I take medication for hot flashes long-term?
Yes, in most cases. There’s no fixed duration limit for these medications when used for VMS, and many women take them for years. Your clinician will reassess periodically — particularly for fezolinetant, given the liver-testing requirement — but ongoing use is appropriate as long as benefits outweigh side effects and you and your clinician are reviewing it regularly.
Sources
The Menopause Society. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Internal Medicine. 2014;174(7):1058-1066. (MsFLASH.)
Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289(21):2827-2834.
Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305(3):267-274. (MsFLASH.)
Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102.
Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT (SKYLIGHT 2). Journal of Clinical Endocrinology & Metabolism. 2023;108(8):1981-1997.
The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024.
Disclaimer
This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. All medications discussed in this article — SSRIs, SNRIs (including paroxetine, escitalopram, venlafaxine, desvenlafaxine), gabapentin, oxybutynin, clonidine, and fezolinetant (Veozah) — require evaluation and prescription by a clinician. They are not appropriate for everyone, can interact with other medications, and have specific contraindications and monitoring requirements. Do not start, stop, or change a prescription medication without speaking to your clinician.
